Today, the micro-factory concept of downsizing production systems is essential to manufacturing small products in sustainable growth. Concerning this, this paper presents the developments accomplished during the recent years at Tecnológico de Monterrey (Mexico) and Holguin University (Cuba) introducing new findings related to the design of reconfigurable micro-factories based-on micro-machine tools. The chapter discusses the proposed framework for the optimizing the development of micro-factories in the context of micro-reconfigurable manufacturing systems based-on micro-reconfigurable machine tools. The novel methodology for optimizing the scheduling of reconfigurable micro-factories were exposed and a scheduling optimization of a reconfigurable micro-factory prototype was designed and tested.
BackgroundSystemic Lupus erythematosus (SLE) is an autoimmune disease mediated by the deposit of immune complexes of autoantibodies which are potentially inflammatory since they can activate the innate immune response through binding to FcgR. The SLE prevalence is 80 per 1 00 000 inhabitants, this prevalence is similar in other population groups, however, the presence of Lupus Nephritis is particularly high in Mexicans (60% of renal disease compared to 12% in Caucasian population), this data is relevant since the diversity of susceptibility genes that have been identified in Mexican patients are from Caucasian origin, despite this the lupus phenotype in Mexican Mestizo is different to any other population. The most important thing to consider is the impact that lupus nephritis causes in health status and quality of life of patients. In this study, the aim was to investigate whether the distribution of the FcgRIIa polymorphisms determines susceptibility to lupus nephritis, the main clinical manifestation in mestizo Mexican patient.MethodsA total of 111 patients that fulfilled the American College of Rheumatology (ACR) classification criteria for SLE and 102 healthy volunteers have been included in this study.FCGR2A genotypes were determined by polymerase chain reaction-based allotyping methods with allele-specific probes; the clinical features were obtained from patients official medical records.ResultsAbout polymorphism, when different groups of patients were compared: SLE with and without renal activity (defined as ACR criteria) there were found statistical differences between the groups, the genotype RR-131 (p=0.04, OR=3.61) was increased in patients with renal activity or history of this clinical manifestation. Additionally, it was found that the patients classified by biopsy with proliferative membrane glomerulonephritis, were mostly the patients with the GG genotype (60%).Abstract 75 Table 1FcgIIa genotypes in SLE patients. LEG +act renal LEG sin act. Renal n=77 n=34 pC OR IC95% Genotipos n (frecuencia) n (frecuencia) R131/R13125 (0.32)4 (0.12) 0.04 3.61 1.15–11.35 R131/H13141 (0.53)19 (0.56)NSH131/H13111 (0.15)11 (0.32) 0.05 0.35 0.13–0.91 Comparison of FcgIIa genotypes among patients who have presented renal activity compared with patients who have not presented renal activity.ConclusionsThe results demonstrate that FcgRIIa polymorphism is associated with susceptibility to lupus nephritis in Mexican patients. The hypothesis for this association could be related to the role of this receptor in the clearance of immune complexes, mainly by innate immune cells like neutrophils which have been identified in biopsies of these patients. Additionally, the activation of this receptor by the engage with immune complexes activate different immune lineage cells which function is affected by the presence of polymorphisms. Functional studies are necessary to determine how this polymorphism affects the effector activity of these cells and the consequences in renal tissue.Funding Source(s)...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.